It is estimated by the WHO that a third of the global population is infected with M. tuberculosis. Each person carrying latent TB infection (LTBI) has approximately a 10% chance of progression to active TB disease. This risk is elevated among certain groups, including those who have been recently infected and those who have clinical conditions that are associated with an increased risk for progression of LTBI to active TB.
HARNESSING THE POWER OF T CELLS
The proprietary T-SPOT technology, derived from the ELISPOT platform, measures immune cell responses at a single cell level. The technology detects T cell activation through cytokine release to assess the patient’s immune system.
THE T-SPOT.CMV TEST
The T-SPOT®.TB test is an in vitro diagnostic test for the detection of effector T cells that respond to stimulation by Mycobacterium tuberculosis antigens ESAT-6 and CFP 10 by capturing interferon gamma (IFN-γ) in the vicinity of T cells in human whole blood collected in sodium citrate or sodium or lithium heparin.
|Manufacturer||Oxford Immunotec (UK)|